Related Experiment Video

Updated: Jun 2, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Mammalian target of rapamycin as a target in hematological malignancies

Kevin R Kelly1, Julie H Rowe, Swaminathan Padmanabhan

  • 1Institute for Drug Development, Cancer Therapy & Research Center, University of Texas Health Science Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA. KellyKR@uthscsa.edu

Targeted Oncology
|April 19, 2011
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway shows promise for treating blood cancers. New drugs inhibiting both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) may improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for regulating protein synthesis, cell growth, and proliferation.
  • The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway plays a significant role in the pathogenesis of hematological neoplasms.
  • Current agents targeting this pathway have demonstrated modest responses in clinical trials for leukemia and lymphomas.

Purpose of the Study:

  • To review the role of the PI3K/Akt/mTOR pathway in hematological malignancies.
  • To evaluate the efficacy of current mTOR inhibitors in treating these cancers.
  • To explore the potential of novel therapeutic strategies targeting mTOR.

Main Methods:

  • Review of existing literature on mTOR pathway signaling in hematological neoplasms.
  • Analysis of clinical trial data for mTOR inhibitors in leukemia and lymphoma.
  • Discussion of emerging therapeutic agents targeting mTOR complexes.

Main Results:

  • mTOR pathway dysregulation is implicated in the development of hematological cancers.
  • Clinical trials of mTOR inhibitors have shown limited but notable responses in patients.
  • Further research is needed to optimize therapeutic strategies.

Conclusions:

  • Targeting the mTOR pathway is a viable strategy for treating hematological malignancies.
  • Developing novel agents that inhibit both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) may enhance therapeutic efficacy.
  • Simultaneous inhibition of mTORC1 and mTORC2, or targeting AKT alongside mTOR, presents a promising avenue for improving treatment outcomes in patients with leukemia and lymphomas.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: